Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

Part of paid clinical trials in Southfield, Michigan.

Sponsor
St. John Providence Health System
Study ID
NCT00150657
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — DRUG
  • carboplatin — DRUG
  • gemcitabine — DRUG

Study Details

* this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added * the study will measure the time to progression of patients treated with the combination; we hope to show that the addition of bevacizumab improves the time to progression (increases the amount of time before the disease begins to worsen) * all patients receive all three drugs; there is no placebo

Key Dates

First listed
Sep 8, 2005
Start date
Nov 30, 2004
Status verified
Sep 2005

Study Design

Enrollment
45 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

time to progression

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Providence Cancer InstituteSouthfieldMichigan48075
Michael J Kraut, MD
[email protected]
248-849-8155
Howard Terebelo, DO
248-552-0620
Michael J Kraut, MD (PRINCIPAL_INVESTIGATOR)
Howard Terebelo, DO (SUB_INVESTIGATOR)
Anibal Drelichman, MD (SUB_INVESTIGATOR)
Robert Bloom, MD (SUB_INVESTIGATOR)
Lyle Goldman, MD (SUB_INVESTIGATOR)
Judie Goodman, DO (SUB_INVESTIGATOR)

Find similar trials in Southfield, MI

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Providence Cancer Institute· Southfield, MI

Related Studies